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H5N1 virusEdible vaccines that can be made widely available and easily administered could bring great beneﬁt to the
worldwide battle against pandemic viral infections. They can be used not only for the vaccination of humans
and domesticated animals, but also for wild herds and live stock which are otherwise difﬁcult to vaccinate. In
this study, we report the development of an edible mini-capsule form of live, non-persisting, recombinant
Lactococcus lactis (L. lactis) vaccine against the highly virulent inﬂuenza H5N1 strain. Recombinant L. lactis-
based H5N1 HA antigen expression constructs were made and shown to be able to induce higher levels of
HA-speciﬁc serum IgG and fecal IgA antibody production after oral administration. The vectors were then
formulated into a mini-capsule dosage form and fed to mouse. Four doses of oral administration rendered
complete protection of the mouse against lethal challenges of H5N1 virus.ur Road, Wanchai, Hong Kong,
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
The highly pathogenic avian inﬂuenza H5N1 virus is considered a
great threat to worldwide human and animal health. This virus strain
is highly susceptible to antigen drift and shift and has already caused
several outbreaks in human subjects with very high mortality rate
(Duan et al., 2008; Subbarao et al., 1998). Vaccination is considered
the most desirable counteraction to prevent the spreading and rapid
mutation of the virus. It is also highly preferable to develop vaccines
for all the species affected to slow down the cross-species spreading.
However, conventional inﬂuenza vaccinesmade of inactivated viruses
could hardly be useful for the H5N1 strain because of difﬁculties in
manufacturing and the general requirement of multiple injections to
every subject (Bright et al., 2003; Johansson et al., 2006; Kilbourne et
al., 2002). New vaccine preparations, including various subunit
vaccines (Wei et al., 2008), DNA vaccines (Chen et al., 2008; Kong
et al., 2006) and recombinant adenovirus vaccines (Gao et al., 2006;
Hoelscher et al., 2006) are being examined, but they all require
injection which would be impossible for wild birds and costly and
troublesome for humans and farm animals. In this regard, safe and
efﬁcacious oral vaccines would be ideal since they can be added to the
food or drinks of the subjects to be immunized.There has been a long pursuit of edible vaccines that are safe,
effective and convenient to use. We had previously proposed the use of
edible plants such as tomato and potato to express antigens that could
be taken orally for the vaccination of human and livestock animals (Lam
and Shi, 1996; Lam et al., 1997; Mason et al., 1992). Recently, rice was
used as the antigen expression and delivery vehicle and showed to
convey immunity against cholera inmice (Nochi et al., 2007). The use of
edible plants as expression anddelivery vehicles for vaccines offermany
advantages, for a variety infectious diseases, especially those whose
pathogens are relatively conserved. This is because it normally takes
over 1 year to produce stably expressed transgenic plants. In contrast,
for diseases inwhich the infective virusesmutate or shift rapidly, suchas
the inﬂuenzaviruses, expression vehicles that are bothedible and canbe
transformed in a matter of weeks are muchmore desirable. It is mainly
for this reason that we chose the lactic acid bacteria (LAB) which is
generally regarded as safe (GRAS) andwidely consumed or used in food
products. This approachhas been reported in studies using recombinant
Lactococcus lactisencodingvarious antigens for oral administration (Cho
et al., 2007; Gilbert et al., 2000; Robinson et al., 1997; Xin et al., 2003),
resulting in a variety of immune responses thought to be related to the
type of antigen, the amount of antigen expressed, and the duration of
antigen expression in the gut (Gruzza et al., 1994; Klijn et al., 1995).
In this study, we constructed two inﬂuenza H5N1 hemagglutinin
(HA) antigen expression vectors based on a well-engineered nisinA-
induced L. lactis expression strain. They either expressed the antigen
in the cytoplasm (L2), or secreted the antigens (L3). These vectors
were formulated with mucoadhesive polymers and packaged in
Table 1
The relative live Lactococcus lactis count after simulated gastric ﬂuid treatment.
L. lactis vector Live bacteria number (CFU)
L1 3.5×104
L2 3.6×104
L3 3.8×104
Capsule-L1 109
Capsule-L2 109
Capsule-L3 109
320 H. Lei et al. / Virology 407 (2010) 319–324enteric-coated mini-capsules (mm size). After oral administration of
the enteric-coated antigen-secreted expression vector, the resulted
immune responses were greatly improved, resulting in complete
protection of the immunized mice from a lethal dose of viral
challenge.
Results
Inﬂuenza H5N1 HA antigen gene expression by recombinant L. lactis
Three different L. lactis vectors were constructed and named L1
(empty vector), L2 (non-secretion) and L3 (secretion), respectively.
Western blot analysis showed the L1 as a control vector which does
not express any HA (Fig. 1C), and L2 expressed the HA protein
(64 kDa) which was found in the cell lysate and no detection in
supernatant (Fig. 1C). L3 had an usp45 signal sequence cloned before
the HA gene, so expressed HAs were found in the cell lysate and the
culture supernatant (Fig. 1C). These results supported that antigen
proteins were correctly expressed and located.
Enteric capsule preparation and L. lactis release in simulated
gastrointestinal (GI) environment
About 109 CFU of recombinant L. lactis vectors (109 CFU) were
packaged in enteric capsules (mini-capsule), each measuring about
4×1 mm in size. The samples were named capsule-L1, capsule-L2 and
capsule-L3, respectively. The capsule samples as well as solutionFig. 1. Secretory and non-secretory vectors construct and expression of HA antigen gene
expression plasmid pNZ8110 that contained secretion signal sequence ssUSP, to produce
secretory expression plasmid pNZ8110 (NcoI/HindIII). (C) Secretion and non-secretion e
supernatant, respectively. M: pre-staining marker, Lane 1: L1 (control), Lane 2: L2(non-secsampleswere treatedwith simulated gastric ﬂuid at pH 1.0 for 2 hours
and then released in simulated intestinal buffer at pH 6.8 for 45 min.
The resulted live L. lactis cell counts (CFU) were listed in Table 1. The
capsule groups showed strong acid resistance and survived at pH 1.0
with a small loss of viable cell numbers, while the solution groups had
drastically reduced live vector counts (N20000-fold) after the
treatments. These results indicated enteric capsules are helpful and
necessary for delivery of the recombinant L. lactis to the intestine
escaping the degradation of stomach acid.
HA-speciﬁc IgG and IgA responses after oral administration
The mice were immunized four times at weeks 0, 2, 4 and 6 by oral
administration of the recombinant L. lactis solutions or enteric
capsules. Immunization dose was 109 CFU of the recombinant L. lactis
in solutions or capsule forms containing the same amount of theon Lactococcus lactis. (A) A 1704-bp HA gene fragment was fused with the secretory
pNZ8110 (NaeI/HindIII). (B) After ssUSP was deleted by NcoI/HindIII digestion, non-
xpression on L. lactis were conﬁrmed by western blot analysis in the cell lysate and
retion), Lane 3: L3(secretion).
Fig. 2. HA-speciﬁc antibody titers detected by ELISA. Mice were orally immunized with
enteric capsules and non-enteric live bacteria. (A) HA-speciﬁc serum IgG was
determined by ABS-ELISA using recombinant HA protein as a coating antigen. (B)
HA-speciﬁc mucosal IgA was determined from the fecal pellets. *Statistically signiﬁcant
differences relative to the PBS, L1 and capsule-L1 controls (*pb0.05). Data are given as
mean±SD of duplicate experiments. n=5 mice per group.
Table 2
Neutralization assay of H5N1 virus with immune serum (n=5 mice per group).
Mice orally immunized with Neutralization titer of serum (IC50)
PBS b10
L1 b10
L2 47
L3 68
Capsule-L1 b10
Capsule-L2 80
Capsule-L3 148
Fig. 3. Cell-mediated immune responses induced by enteric-coated recombinant
Lactococcus lactis. *Statistically signiﬁcant differences relative to the PBS, L1 and
capsule-L1 controls. Data are represented as mean±SD of triplicate experiments. n=5
mice per group.
321H. Lei et al. / Virology 407 (2010) 319–324recombinant L. lactis solutions (109 CFU). HA-speciﬁc serum IgG and
fecal IgA levels were measured 10 days after the last immunization
dosing.
The mean log2 titers of serum IgG of all the tested groups were
shown in Fig. 2A. All the HA expressing vectors (solution and
capsules) resulted in signiﬁcant production of HA-speciﬁc serum
IgG, while PBS and L1 samples did not. In general, encapsulated
groups (capsule-L2 and capsule-L3) had higher titers than the
corresponding solution groups. The group dosed with capsule-L3
reached the highest antibody titer, 11.2±0.837, and signiﬁcantly
higher than capsule-L2, 6.6±1.14.
To examine the HA-speciﬁc mucosal immune response, the
production of mucosal IgA antibody was examined using fecal pellets
(Fig. 2B). Again, the enteric capsule groups all developed signiﬁcant
IgA antibody responses. The capsule-L3 gave the best results.
Neutralizing antibody titers in mice
The neutralizing antibody titers in each treatment groups were
measured using themicroneutralization (MN)method. Neutralizationtiters values of the enteric capsule groups (capsule-L2, and capsule-
L3) were all higher than 80, suggesting good neutralization activities
of the antibodies generated (Table 2).
Antigen speciﬁc T cell responses
We also used the IFN-γ ELISpot assay to examine the HA-speciﬁc T
cell response resulted from recombinant L. lactis after oral adminis-
tration. Splenocytes (106 cells) from each treatment group were
collected and stimulated with 10 μg/ml of HA epitope peptide
(ISVGTSTLNQRLVP). The resulted IFN-γ expressing T cell numbers
were counted and plotted in Fig. 3. Again, therewere HA-speciﬁc T cell
responses generated by oral administration of enteric-coated recom-
binant L. lactis. The encapsulated groups (capsule-L2 and capsule-L3)
were much more effective than the respective solution groups. These
results revealed capsule-L2 and capsule-L3 not only induced humoral
and mucosal immune, but also produced cellular immune.
H5N1 virus challenge experiment
Two weeks after the ﬁnal immunization, the mice were intrana-
sally challenged with lethal doses of highly pathogenic H5N1 viruses
and closely monitored for 14 days for weight loss and mortality. After
viral challenge, all mice experienced certain levels of body weight loss
(Fig. 4A), but mice immunized with capsule-L3 gradually recovered
after 8 days and 100% survival. In contrast, the naïve mice (PBS
treated) and mice immunized with the empty plasmid vector (L1 and
capsule-L1), all died within 10 days of challenge (Fig. 4B).
Fig. 4. Immune protection against H5N1 virus lethal challenges after oral deliveries of
different vaccine preparations. Mice were infected intranasally with H5N1 virus
2 weeks after the last immunization. (A) Mean weight loss (%) of mice 6 days after
infection. (B) Percent survival of mice 0–14 days after infection. *Statistically signiﬁcant
differences relative to the PBS, L1 and capsule-L1 controls. n=5 mice per group.
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For viral infections, such as the H5N1 inﬂuenza virus which affects
humans as well as many animal species, it is highly desirable to
develop safe and efﬁcacious edible vaccine formulations that can be
produced economically and applied conveniently. In addition, since
inﬂuenza viruses naturally infect through the mucosa, it is also highly
desirable to develop vaccines that can induce mucosal immune
responses as well as systemic responses. Mucosal vaccine delivery by
the oral route is considered the most convenient method, but most
viruses and protein antigens are quickly degraded in the gastrointes-
tinal system. They might also not be immunogenic enough to elicit
signiﬁcant or clinically important immune responses.
Different antigen carrier systems have been proposed, including
recombinant plants, bacteria or virus-based vectors for the production
and presentation of the antigens (Cho et al., 2007;Mason et al., 1992). In
addition, various polymer and lipidmicrospheres have beenused for the
protection and controlled release of protein antigens in the gut. In this
study, we have combined these two approaches to produce an oral
vaccine that is effective against H5N1 infection in mice and probably in
chicken as well. The recombinant L. lactis vectors were ideal to produce
large quantities of antigens and deliver them orally to the gut.Considering that the gastric environment would still be somewhat
hostile to L. lactis viability, we have developed an enteric-coated
polymer capsule formulation of a small enough size (mm) tobe ingested
even by mice or chickens. Our results indicate that this formulation
indeed produces a great improvement on the overall immunogenicities
of the vaccines, resulting in complete protection and survival of mice
injected with an otherwise lethal dosage of H5N1 virus.
For the production and delivery of antigens, genetically engineered
live vector systems have many advantages in manufacturing and
processing. About 20 years ago, Lam and his colleagues initiated the
plant-based vaccine development and showed the feasibility of using
plants to express HBV surface proteins and viral particles to be used as
vaccines (Lam and Shi, 1996; Lam et al., 1997; Mason et al., 1992).
More recently, there was a study using rice grain as the delivery
vehicle. The protein antigens were shown to be well protected and
maintained stable in rice without requirements for refrigeration
(Nochi et al., 2007). Good stability of oral vaccines under ambient
conditions is clearly important for the distribution of vaccines to
remote areas of the world.
Alternatively, bacteria-based systems such as Salmonella, Borte-
della and Listeria spp. have also been studied extensively as antigen
expression and delivery carriers. Most of them were originally
pathogenic strains so they may be more immunogenic or express
stronger immune responses. In contrast, the lactic acid bacteria
(LAB)-based vectors are considered safer, but may not be as
immunogenic for the human immune system. Some studies have
suggested the ability of certain LAB vectors to persist in the GI tract is
critical for the effectiveness of vaccines. Grangette et al. (2002)
conducted a direct comparison of Lactococcus plantarum, a persisting
LAB, and L. lactis, a non-persisting LAB and found L. plantarum to be
more effective at eliciting antigen-speciﬁc immunity. Many other
studies employed Lactococcus casei-based vectors which could also
persist in human GI microbiota. However, the use of persisting
bacteria might not be desirable as vehicles for edible vaccines as
special consideration would be needed for biocontainment purposes
(Steidler et al., 2003).
The uniqueness of the present study is the successful creation of an
edible vaccine against an inﬂuenza virus (H5N1) using a non-
persisting L. lactis (Kimoto et al., 2003) as the carrier, loading them
on mucoadhesive polymers and packaging them in enteric-coated
mini-capsules. We showed that although the viability of L. lactis is
rapidly diminished in the gastrointestinal tract, the antigens they
carried and produced shortly after they were administered and
protected temporarily by the encapsulation were sufﬁcient to induce
signiﬁcant mucosal and systemic immune responses and allow all the
mice to survive the lethal in mice and chickens, challenge of H5N1
injection.
It is possible that the vector systems themselves had speciﬁc
immune stimulation effects. It has been shown that LAB can initiate
inﬂammatory responses and activate monocytes and other antigen
presenting cells (Mercenier et al., 2003). In our study, different
immune responses resulted from similar vector systems which
differed only in antigen expression designs were observed. The
mini-capsule form of the HA antigen expression and secretion
vector (capsule-L3) gave the best response in every aspect after. For
avian inﬂuenza strains, the analysis of sera from mice supports the
use of a neutralizing titer of ≥80 as an efﬁcacy endpoint
(Eichelberger et al., 2007). In this study, the neutralization titer of
capsule-L2 was 80 and the survival rate was 40% after H5N1
infection. In contrast, neutralization titer of capsule-L3 was 148 and
provided 100% protection against H5N1 virus challenge. Similar
plans for H5N1 challenges in chickens are in progress pending
regulatory approvals.
The inﬂuenza HA antigen gene (AY950232 in GenBank) we cloned
in our vectors is from A/chicken/Henan/12/2004(H5N1). The
enteric-coated mini-capsule dosage forms could result in signiﬁcant
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tion from H5N1 virus challenge. The nisinA-induced recombinant L.
lactis antigen expression vectors we used are very ﬂexible in design
and can be optimized for antigen expression and presentation. It is
also a well-engineered stable system for large scale production
(Bahey-El-Din et al., 2008; De Ruyter et al., 1996). The polymer mini-
capsule formulation we developed was also easy and inexpensive to
manufacture. Although it is a simple design, the improvement in
vaccine efﬁcacy was highly signiﬁcant.
Materials and methods
Construction of recombinant L. lactis expressing HA gene
The L. lactis expression plasmid pNZ8110 was purchased from
NIZO, Netherlands. The HA gene fragment (1704 bp) was ampliﬁed
from pGEM-HA (kindly supplied by Prof. Ze Chen, Wuhan, China) by
PCR using the following primer pairs with NaeI or HindIII sites
underlined (forward primer: 5'tctgccggcgagaaaatagtgcttctt3', reverse
primer: 5'cccaagcttttaaatgcaaattctgcattgtaacg 3'). The resulting NaeI/
HindIII fragment was cloned into pNZ8110 containing the secretion
signal ssUSP (Fig. 1A). Another plasmid was constructed by replacing
the forward primer with the following primer containing an NcoI site
underlined (5'catgccatggagaaaatagtgcttctt3'). The resulting NcoI/
HindIII fragment was sub-cloned into pNZ8110 so that the ssUSP
was deleted (Fig. 1B).
These plasmids were then individually transformed into the L. lactis
NZ9000 stains by electroporation. The most highly expressed clones
were selected and banked. The L. lactis vector transfected with the
empty plasmid pNZ8110 was designated as L1. The vector transfected
with the HA expressing plasmid without the ssUSP sequence was
designated as L2. The one transfected with the HA expressing plasmid
containing the ssUSP sequence was designated as L3.
All the L. lactis stains were cultured at 30 °C in M17 medium
supplementedwith 0.5% (wt/vol) glucose. Chloramphenicol was used
at a concentration of 10 μg/ml.
Western blot analysis
The HA antigen expression levels in the L. lactis cultures were
analyzed by Western blot analysis. NisinA were added into the culture
medium to the ﬁnal concentration of 1 ng/ml to induce antigen
expressions. The cultures were maintained for 3 more hours and the
supernatants were harvested. The harvested L. lactis cells pellets were
washed three timeswith 500 μl sterile phosphate-buffered saline (PBS),
and resuspended. Aliquots of the samples (either cell suspensions or
supernatants) were mixed with 6× loading buffer and boiled 10 min.
Extracts were run on SDS–PAGE (10% acrylamide) and transferred to
polyvinylidene diﬂuoride membrane (PVDF, Millipore, USA). Protein
was detected using polyclonal mouse anti-HA antibody followed by
afﬁnity-puriﬁed horseradish peroxidase (HRP)-conjugated anti-mouse
IgG (R&D Systems). The membrane was radiographed on X-ﬁlm using
the ECL Western Blotting Detection System according to the manufac-
ture's recommendations (Pierce, USA).
Preparation and analysis of the enteric-coated mini-capsule forms of
L. lactis vectors
L1, L2 and L3 were prepared into solutions with the concentration
of 1011 colony-formation units (CFU)/ml, respectively. Tenmicroliters
of the recombinant L. lactis solution containing 1×109 CFUwas mixed
with 0.5 mg of BSA and methyl cellulose (MC), air dried and packaged
into enteric-coated capsules and named capsule-L1, capsule-L2,
capsule-L3, respectively.
For the analysis of the capsule integrity, the capsules were
immersed in simulated gastric ﬂuid at pH 1.0 with low speed agitationfor 2 hours and then dropped into phosphate buffer at pH 6.8 for
45 min to release the encapsulated contents. Viable cells were
counted by gradient dilution methods.
Animals and animal immunizations
Six-week-old female BALB/c mice were purchased from China
SLC, Shanghai, China. The mice were housed in the speciﬁc
pathogen-free (SPF) Animal Center of Shanghai Jiao Tong University.
They were divided into 5 mice per experimental group. Before each
dose, they were fasted for 6 h and then administer 10 μl of the
recombinant L. lactis solution or 1 capsule containing 1011 CFU of the
respective recombinant L. lactis vectors using a 21-gauge feeding
tube. Immunizations were repeated at 2, 4 and 6 weeks after the
initial dosing.
ELISA assay
Sera were collected 10 days after the last dosing. HA-speciﬁc
antibody responses were detected by avidin-biotin system (ABS)-
enzyme-linked immunosorbent assay (ELISA) (Katz et al., 1997). The
10-μg/ml inﬂuenza A virus (A/chicken/Henan/12/2004(H5N1))
recombinant HA protein was used to coat 96-well microplates. At
the same time, fecal pellets (50 mg) for each group of ﬁve mice were
collected and suspended in 250 μl sterile PBS, centrifuged down at
15,000× rpm for 10 min, and the supernatants tested for IgA by
indirect ELISA. The mean antibody titer was expressed as the highest
dilution that yielded an optical density greater than twice the mean
plus one standard deviation of that of similarly diluted negative
control samples.
IFN-γ ELISpot assay
The IFN-γ ELISpot assay was performed one week after the ﬁnal
immunization using an ELISpot kit for mouse IFN-γ as recommended
by the manufacturer (R&D Systems, USA). Brieﬂy, mouse IFN-γ
microplate was added 200 μl/well of sterile culture media and
incubated for 20 min at room temperature. After aspirating the
culture media from the wells, the plates were added 100 μl of 1×106
splenocytes per well. The 10 μg/ml of HA-speciﬁc peptide
(ISVGTSTLNQRLVP) was used as stimuli for 48 h in a humidiﬁed
37 °C CO2 incubator. Control wells were not stimulated with HA-
speciﬁc peptide. After incubation, each well was aspirated and
washed, the plates were treated sequentially with biotinylated anti-
mouse IFN-γ antibody, alkaline phosphatase conjugated streptavidin
and the substrate solution to reveal the spots. The developed
microplate could be analyzed by counting spots using a dissection
microscope.
Neutralization assay
Determination of endpoint neutralizing antibody titers was
performed by microneutralization assay, as previously described
(Rowe et al., 1999). Brieﬂy, serial 2-fold dilutions of sera treated with
receptor-destroying enzyme (RDE) from Vibro cholerae were mixed
and incubated with 35 μl 100 50% tissue culture infective doses
(TCID50) of H5N1 virus, then added to Madin–Darby canine kidney
(MDCK) cells and incubated for 1 h. The H5N1 virus-infected MDCK
cells were further cultured for 72 h at 37 °C in the presence of 5% CO2,
and the neutralizing titer was determined by hemagglutination test.
For the HA test, 50 μl of 0.5% cock red blood cells was added to 50 μl of
cell culture supernatant and incubated at room temperature for
30 min. The TCID50 was determined on the basis of the Reed–Muench
method (Rohm et al., 1995). The neutralization titer (IC50) was
deﬁned as the reciprocal of the antiserum dilution at which H5N1
virus entry was 50% inhibited.
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For the challenge experiment, mice were anesthetized and
intranasally challenged with 20 μl 10×50% lethal dose (LD50) H5N1
virus 2 weeks after the last immunization. After infection, the mice
were weighed and monitored for signs of illness for 14 days. The
challenge experiments were strictly performed under biosafety level-
3-plus enhancement conditions.
Statistical analysis
Statistical analysis of the experimental and control data were
performed by one-way factorial analysis of variance. P-values less
than 0.05 were considered as a statistical signiﬁcance.
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